Abstract:Peptides are receiving increasing interest as clinical therapeutics. These highly tunable molecules can be tailored to achieve desirable biocompatibility and biodegradability with simultaneously selective and potent therapeutic effects. Despite challenges regarding up-scaling and licensing of peptide products, their vast clinical potential is reflected in the 60 plus peptide-based therapeutics already on the market, and the further 500 derivatives currently in developmental stages. Peptides are proving effective for a multitude of disease states including: type 2 diabetes (controlled using the licensed glucagon-like peptide-1 receptor liraglutide); irritable bowel syndrome managed with linaclotide (currently at approval stages); acromegaly (treated with octapeptide somatostatin analogues lanreotide and octreotide); selective or broad spectrum microbicidal agents such as the Gram-positive selective PTP-7 and antifungal heliomicin; anticancer agents including goserelin used as either adjuvant or monotherapy for prostate and breast cancer, and the first marketed peptide derived vaccine against prostate cancer, sipuleucel-T. Research is also focusing on improving the biostability of peptides. This is achieved through a number of mechanisms ranging from replacement of naturally occurring L-amino acid enantiomers with D-amino acid forms, lipidation, peptidomimetics, N-methylation, cyclization and exploitation of carrier systems. The development of self-assembling peptides are paving the way for sustained release peptide formulations and already two such licensed examples exist, lanreotide and octreotide. The versatility and tunability of peptide-based products is resulting in increased translation of peptide therapies, however significant challenges remain with regard to their wider implementation. This review highlights some of the notable peptide therapeutics discovered to date and the difficulties encountered by the pharmaceutical industry in translating these molecules to the clinical setting for patient benefit, providing some possible solutions to the most challenging barriers.

Towards the Development of Orally Available Peptide Therapeutics.

Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches

Overcoming the shortcomings of peptide-based therapeutics

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

De Novo Development of Proteolytically Resistant Therapeutic Peptides for Oral Administration

Progress in Research on Oral Delivery of Peptide Drugs

Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients

Progress in the Study of Oral Delivery of Protein and Peptide Drugs

Challenges and opportunities in delivering oral peptides and proteins

Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

Are membrane-interacting peptides viable as excipients for non-injectable peptide delivery?

Nano and Microscale Delivery Platforms for Enhanced Oral Peptide/protein Bioavailability.

Peptide therapeutics: Targeting the undruggable space

Peptides for therapeutic applications – challenges and chances

The industrial design, translation, and development strategies for long-acting peptide delivery

Nano and microscale delivery platforms for enhanced oral peptide/protein bioavailability

Obstacles, Research Progress, and Prospects of Oral Delivery of Bioactive Peptides: a Comprehensive Review

Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Cyclic peptide therapeutics: past, present and future